Table 2 ADRs of long-term VPA monotherapy in children with epilepsy (n = 740)
From: The safety of valproic acid treatment in children with epilepsy: a retrospective real-world research
ADRs | Patients with positive ADRs (n) | Before treatment (%) | After treatment (%) |
|---|---|---|---|
Attention defect | 33 | 18 (2.43) | 15 (2.03) |
Nasal bleeding | 16 | 2 (0.27) | 14 (1.89) |
Fracture | 15 | 4 (0.54) | 11 (1.48) |
Enuresis | 9 | 3 (0.41) | 6 (0.81) |
Hyperammonemia | 7 | 1 (0.14) | 6 (0.81) |
Liver damage | 4 | 0 (0.00) | 4 (0.54) |
Abnormal uterine bleeding | 3 | 1 (0.40) | 2 (0.80) |
Amenorrhea | 1 | 0 (0.00) | 1 (0.40) |
Menstrual disturbance | 1 | 1 (0.40) | 0 (0.00) |